Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Evolus	CytomX Therapeutics	Forte Biosciences	Molecular Templates	TherapeuticsMD
Symbol	NASDAQ:EOLS	NASDAQ:CTMX	NASDAQ:FBRX	NASDAQ:MTEM	NASDAQ:TXMD
Price Information
Current Price	$9.14	$8.55	$32.64	$8.81	$1.09
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.5	1.6	1.7	2.0	1.5
Analysis Score	4.3	3.4	3.5	3.4	3.2
Community Score	2.8	2.8	3.5	2.6	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.8	3.3	0.8
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$15.00	$12.07	$82.00	$14.50	$5.07
% Upside from Price Target	64.11% upside	41.19% upside	151.23% upside	64.59% upside	364.83% upside
Trade Information
Market Cap	$399.77 million	$555.78 million	$441.03 million	$494.14 million	$428.58 million
Beta	2.69	0.74	0.23	2.08	2.19
Average Volume	1,458,275	1,069,368	176,442	443,700	13,368,902
Sales & Book Value
Annual Revenue	$34.92 million	$57.49 million	$40,000.00	$22.27 million	$49.65 million
Price / Sales	11.45	9.67	11,025.79	22.19	8.63
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.38 per share	$1.12 per share	$6.81 per share	$2.79 per share	$0.03 per share
Price / Book	3.84	7.63	4.79	3.16	36.33
Profitability
Net Income	$-90,030,000.00	$-102,240,000.00	$-63,520,000.00	$-69,420,000.00	$-176,150,000.00
EPS	($3.19)	($2.26)	($40.33)	($1.26)	($0.68)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-120.63%	-58.13%	N/A	-428.65%	-327.98%
Return on Equity (ROE)	-121.11%	-94.20%	-417.87%	-111.43%	N/A
Return on Assets (ROA)	-30.91%	-13.79%	-248.28%	-56.35%	-78.47%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	3.25%	N/A	N/A	0.18%	N/A
Current Ratio	10.42%	3.34%	8.97%	3.21%	2.59%
Quick Ratio	10.03%	3.34%	8.97%	3.21%	2.38%
Ownership Information
Institutional Ownership Percentage	21.66%	77.87%	53.03%	60.73%	52.56%
Insider Ownership Percentage	10.10%	5.80%	10.90%	38.20%	13.76%
Miscellaneous
Employees	119	144	9	228	400
Shares Outstanding	43.74 million	65.00 million	13.51 million	56.09 million	393.19 million
Next Earnings Date	5/12/2021 (Confirmed)	8/5/2021 (Estimated)	5/10/2021 (Confirmed)	5/10/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	TherapeuticsMD (NASDAQ:TXMD) Announces Earnings Results, Misses Expectations By $0.01 EPS americanbankingnews.com - May 8 at 2:58 PM
	TherapeuticsMD Inc (TXMD) Up 5.41% in Premarket Trading - InvestorsObserver investorsobserver.com - May 8 at 12:21 PM
	TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume - Yahoo Finance finance.yahoo.com - May 7 at 3:38 PM
	TherapeuticsMD Announces First Quarter 2021 Financial Results - BioSpace biospace.com - May 7 at 10:38 AM
	TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript - Motley Fool fool.com - May 7 at 10:38 AM
	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance finance.yahoo.com - May 7 at 10:38 AM
	TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript fool.com - May 7 at 1:39 AM
	TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume - Benzinga benzinga.com - May 7 at 12:37 AM
	TherapeuticsMD: Q1 Earnings Snapshot - SFGate sfgate.com - May 6 at 7:37 PM
	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq nasdaq.com - May 6 at 2:36 PM
	How Will the Market React to TherapeuticsMD Inc (TXMD) Stock Getting a Bullish Rating - InvestorsObserver investorsobserver.com - May 6 at 2:36 PM
	TherapeuticsMD drops 3% despite consensus beating Q1 results - Seeking Alpha seekingalpha.com - May 6 at 2:36 PM
	TherapeuticsMD: Q1 Earnings Snapshot - Westport News westport-news.com - May 6 at 2:36 PM
	TherapeuticsMD Announces First Quarter 2021 Financial Results finance.yahoo.com - May 6 at 2:36 PM
	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com - May 6 at 2:36 PM
	TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume finance.yahoo.com - May 6 at 2:36 PM
	TherapeuticsMD (NASDAQ:TXMD) Shares Gap Down to $1.28 americanbankingnews.com - May 6 at 1:34 PM
	A Preview Of TherapeuticsMD's Earnings - Benzinga benzinga.com - May 5 at 11:07 AM
	TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Yahoo Finance finance.yahoo.com - May 5 at 11:07 AM
	TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Business Wire businesswire.com - May 3 at 8:52 AM
	TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting finance.yahoo.com - May 3 at 8:52 AM
	TherapeuticsMD (TXMD) to Release Quarterly Earnings on Thursday americanbankingnews.com - April 30 at 10:37 AM
	TherapeuticsMD's (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares - Yahoo Finance finance.yahoo.com - April 29 at 5:51 PM
	TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021 - Yahoo Finance finance.yahoo.com - April 29 at 5:51 PM
	TherapeuticsMD's (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares finance.yahoo.com - April 29 at 5:51 PM

Date	Company	Brokerage	Action
5/6/2021	Evolus	Mizuho	Upgrade
4/14/2021	Evolus	HC Wainwright	Reiterated Rating
2/24/2021	Evolus	Truist Financial	Downgrade
2/22/2021	Evolus	Barclays	Boost Price Target
2/22/2021	Evolus	Cantor Fitzgerald	Boost Price Target
2/19/2021	Evolus	Stifel Nicolaus	Boost Price Target
7/7/2020	Evolus	SunTrust Banks	Lower Price Target
4/30/2020	Evolus	Wells Fargo & Company	Lower Price Target
3/29/2021	CytomX Therapeutics	Jefferies Financial Group	Upgrade
3/29/2021	CytomX Therapeutics	JPMorgan Chase & Co.	Initiated Coverage
9/22/2020	CytomX Therapeutics	Guggenheim	Downgrade
9/15/2020	CytomX Therapeutics	Citigroup	Lower Price Target
5/17/2020	CytomX Therapeutics	Nomura	Reiterated Rating
3/24/2020	CytomX Therapeutics	Wedbush	Upgrade
2/28/2020	CytomX Therapeutics	Nomura Securities	Lower Price Target
4/1/2021	Forte Biosciences	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
3/26/2021	Forte Biosciences	(FBRC)	Initiated Coverage
3/23/2021	Forte Biosciences	Chardan Capital	Lower Price Target
8/28/2020	Forte Biosciences	Brookline Capital Management	Initiated Coverage
8/25/2020	Forte Biosciences	Truist Securiti	Initiated Coverage
6/22/2020	Forte Biosciences	LADENBURG THALM/SH SH	Initiated Coverage
4/27/2021	Molecular Templates	Bank of America	Initiated Coverage
4/15/2021	Molecular Templates	Oppenheimer	Lower Price Target
2/1/2021	Molecular Templates	UBS Group	Initiated Coverage
11/13/2019	Molecular Templates	Cowen	Reiterated Rating
12/11/2018	Molecular Templates	CIBC	Initiated Coverage
11/15/2018	Molecular Templates	Evercore ISI	Initiated Coverage
10/8/2018	Molecular Templates	Laidlaw	Initiated Coverage
7/22/2020	TherapeuticsMD	Noble Financial	Reiterated Rating

(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources